Italia - franceză - Unimer

unimer - contenu élevé en carbone organique humifié (carbone humique et fulvique) - engrais écologiques

Italia - franceză - Unimer

unimer - contenu élevé en carbone organique humifié (carbone humique et fulvique) - engrais écologiques

Franța - franceză - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

therabel lucien pharma - titane (dioxyde de) - poudre - 4 g - composition pour un sachet > titane (dioxyde de) : 4 g > camylofine (chlorhydrate de) : 0,030 g

Elveția - franceză - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/tasmania/503/2020), haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) - suspension injectable - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/tasmania/503/2020) 15 µg, haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunisation active contre la grippe, à partir de 36 mois - les vaccins

Elveția - franceză - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021), haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - suspension injectable - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021) 15 µg, haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013-like: b/phuket/3073/2013 wild type (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunisation active contre la grippe, à partir de 36 mois - les vaccins

Elveția - franceză - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022), haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021), haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - suspension injectable - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021) 15 µg, haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013-like: b/phuket/3073/2013 wild type (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunisation active contre la grippe, à partir de 36 mois - les vaccins

Elveția - franceză - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020), haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) - suspension pour injection dans une seringue pré-remplie - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020) 15 µg, haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunisation active contre l'influenza, dès le 6ème mois - les vaccins

Elveția - franceză - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-224 derived from a/cambodia/e0826360/2020), haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) - suspension injectable - haemagglutininum influenzae a (h1n1) (virus-stamm a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-224 derived from a/cambodia/e0826360/2020) 15 µg, haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 6 monaten - les vaccins

Elveția - franceză - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) - suspension pour injection dans une seringue pré-remplie - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021) 15 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: b/phuket/3073/2013, wilde type (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunisation active contre l'influenza, dès le 6ème mois - les vaccins

Elveția - franceză - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) - suspension injectable en seringue préremplie - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 60 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021) 60 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) 60 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage) (wild type)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg. - immunisation active contre l'influenza, dès 65 ans - les vaccins